Remdesivir News and Research

RSS

Casirivimab/imdevimab improve outcomes in early COVID-19

A new Viruses study determines the effect of casirivimab/imdevimab on IFN-1 and cytokines during SARS-CoV-2 infection.

29 Jun 2022

SARS-CoV-2 3CLpro also susceptible to mutations

Researchers assess the activity of all potential mutations in the SARS-CoV-2 3CLpro.

29 Jun 2022

Anticancer drug candidate that targets a human protein could be a pan-viral medication

More than two years into the COVID-19 pandemic, people are realizing that the "new normal" will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.

29 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Scientists have described the development of a modified A549 cell line that shows a robust expression of ACE2 and TMPRSS2 and high susceptibility to SARS-CoV-2 infection.

24 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Determining how SARS-CoV-2, the virus causing COVID-19, moves from an early stage of infection, when patients are largely asymptomatic, into a later stage when people may experience life-threatening inflammation in the lungs, is a critical step in understanding how to target and treat the disease more efficiently.

14 Jun 2022

Study investigates SARS-CoV-2 escape from nirmatrelvir

Researchers assessed SARS-CoV-2 Alpha, Delta, and Omicron variants’ resistance to nirmatrelvir, a protease inhibitor of SARS-CoV-2.

10 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Researchers hypothesized that the emergence of resistant SARS-CoV-2 variants can be anticipated by identifying possible escape mutations already present in the existing SARS-CoV-2 populations.

1 Jun 2022

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers evaluated a drug, atovaquone, for COVID-19 treatment.

30 May 2022

Study explores the substrate selectivity of the SARS-CoV-2 replicase

Researchers explored factors affecting substrate selection by the SARS-CoV-2 replicase.

24 May 2022

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

A new paper presents the results of a mouse study using the repurposed antibacterial drug clofoctol against this virus.

23 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

Remdesivir News and Research

Casirivimab/imdevimab improve outcomes in early COVID-19

SARS-CoV-2 3CLpro also susceptible to mutations

Anticancer drug candidate that targets a human protein could be a pan-viral medication

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

A cancer patient who had SARS-CoV-2 for over eight months

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Insufficient drug exposure most likely to cause COVID-19 rebound

Emory researchers identify key immune cell type that drives the transition from early to late COVID-19

Study investigates SARS-CoV-2 escape from nirmatrelvir

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Researchers evaluate atovaquone as a COVID-19 treatment

Study explores the substrate selectivity of the SARS-CoV-2 replicase

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

Early impact of SARS-CoV-2 on human lungs

CDC study of pregnant women hospitalized with COVID in 2021 found 93% not vaccinated

Research looks at potential of pantethine against SARS-CoV-2

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News